RxDoctor Payments Data

Nossonal Kleinfeldt, MD

Ophthalmology · Livonia, MINPI 1376540369

Payments from drug & device makers

$3,264in general payments, 2019–2025

Across 419 payments — averaging $7.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$194
  • Alcon$114
  • Bausch & Lomb Americas Inc.$109
  • Aerie Pharmaceuticals, Inc.$70
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$48
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$3,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,264 in reported general payments places this provider in the 75th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$649,903
Medicare patients
1,183
Services billed
4,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost526$287,441
Prednisolone Acetate1,244$67,203
Latanoprost2,822$62,389
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol172$57,950
CombiganBrimonidine Tartrate/Timolol107$46,014
RestasisCyclosporine28$31,947
SimbrinzaBrinzolamide/Brimonidine Tart60$19,906
RocklatanNetarsudil Mesylat/Latanoprost33$19,707
Ketorolac Tromethamine1,199$17,911
Cyclosporine19$14,681
Travoprost65$13,708
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat438$13,543
MoxifloxacinMoxifloxacin Hcl667$12,721
Brinzolamide24$8,350
Ofloxacin535$5,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$2,604$365,401661 claims
AlconSimbrinza$114$19,90660 claims
Aerie Pharmaceuticals, Inc.Rocklatan$70$19,70733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →